Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis

被引:0
作者
Chien-Sheng Wu
Chung-Yi Hu
Hwei-Fang Tsai
I-Tsu Chyuan
Cheng-Ju Chan
Sheng-Kai Chang
Ping-Ning Hsu
机构
[1] Far Eastern Memorial Hospital,Department of Internal Medicine
[2] National Taiwan University Hospital,Department of Internal Medicine
[3] National Taiwan University,Graduate Institute of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine
[4] National Taiwan University Hospital,Department of Laboratory Medicine
[5] Taipei Medical University Shuang Ho Hospital,Department of Internal Medicine
[6] Taipei Medical University,Gradute Institute of Clinical Medicine, College of Medicine
[7] National Taiwan University Hospital,Department of Internal Medicine
[8] National Taiwan University,Graduate Institute of Immunology, College of Medicine
来源
Rheumatology International | 2014年 / 34卷
关键词
Growth arrest-specific protein 6 (Gas6); Nephritis; Systemic lupus erythematosus; Vasculitis;
D O I
暂无
中图分类号
学科分类号
摘要
Growth arrest-specific protein 6 (Gas6) is a serum protein involved in granulocyte, platelet and endothelium interaction, and is implicated in both anti-inflammatory response as well as platelet/leukocytes activation. We investigated serum Gas6 level in different clinical manifestations of systemic lupus erythematosus (SLE). Data were collected in 83 patients with SLE and 40 non-lupus controls. The Gas6 levels were detected by enzyme-linked immunosorbent assay. Our results demonstrated that the Gas6 level was higher in SLE patients as compared to the non-lupus control subjects (SLE vs. non-lupus control, median [inter-quartile range (IQR)] 22.67 [19.40–28.60] vs. 18.97 [16.05–20.62] ng/mL, p < 0.01). Furthermore, Gas6 level was higher in patients with nephritis (nephritis vs. non-nephritis, median [IQR] 26.21 [21.17–31.61] vs. 22.22 [18.98–26.98] ng/mL, p = 0.03) and in patients with cutaneous vasculitis (vasculitis vs. non-vasculitis, median [IQR] 27.89 [23.24–34.26] vs. 22.30 [19.32–27.16] ng/mL, p = 0.03). Our results indicate that the serum Gas6 level is increased in SLE patients with lupus nephritis or cutaneous vasculitis, implicating a potential to serve as a SLE disease activity marker.
引用
收藏
页码:625 / 629
页数:4
相关论文
共 146 条
[1]  
Nagata K(1996)Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases J Biol Chem 271 30022-30027
[2]  
Ohashi K(2010)TNF-alpha, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages J Leukoc Biol 87 869-875
[3]  
Nakano T(2005)Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses J Thromb Haemost 3 733-741
[4]  
Arita H(2008)Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes Blood 111 4096-4105
[5]  
Zong C(2012)Genetic polymorphism of the growth arrest-specific 6 gene is associated with cutaneous vasculitis in Taiwanese patients with systemic lupus erythematosus Clin Rheumatol 31 1443-1448
[6]  
Hanafusa H(2010)Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan Lupus 19 1250-1255
[7]  
Mizuno K(2011)Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus Rheumatology (Oxford) 50 1064-1069
[8]  
Alciato F(2013)Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus J Clin Immunol 33 143-150
[9]  
Sainaghi PP(2013)Vitamin K-dependent proteins GAS6 and protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity Arthritis Res Ther 15 R41-1286
[10]  
Sola D(2010)TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus Arthritis Res Ther 12 R146-1277